Terms: = Pancreatic cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Clinical Outcome
3 results:
1. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer.
Tu M; Klein L; Espinet E; Georgomanolis T; Wegwitz F; Li X; Urbach L; Danieli-Mackay A; Küffer S; Bojarczuk K; Mizi A; Günesdogan U; Chapuy B; Gu Z; Neesse A; Kishore U; Ströbel P; Hessmann E; Hahn SA; Trumpp A; Papantonis A; Ellenrieder V; Singh SK
Nat Cancer; 2021 Nov; 2(11):1185-1203. PubMed ID: 35122059
[TBL] [Abstract] [Full Text] [Related]
2. Four-Tier Pathologic Tumor Regression Grading System Predicts the clinical outcome in Patients Who Undergo Surgical Resection for Locally Advanced pancreatic cancer after Neoadjuvant Chemotherapy.
Ahn S; Lee JC; Kim J; Kim YH; Yoon YS; Han HS; Kim H; Hwang JH
Gut Liver; 2022 Jan; 16(1):129-137. PubMed ID: 33875622
[TBL] [Abstract] [Full Text] [Related]
3. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract] [Full Text] [Related]
